1.12

10.89% 0.11

Coherus Biosciences Inc (CHRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CHRS Giù? Forum Previsione

Precedente Chiudi:

$1.01

Aprire:

$1.02

Volume 24 ore:

2.97M

Relative Volume:

1.52

Capitalizzazione di mercato:

$112.95M

Reddito:

$257.24M

Utile/perdita netta:

$-237.89M

Rapporto P/E:

-0.4308

EPS:

-2.6

Flusso di cassa netto:

$-175.17M

1 W Prestazione:

+50.90%

1M Prestazione:

+22.31%

6M Prestazione:

+32.04%

1 anno Prestazione:

-47.91%

Intervallo 1D:

$1.01

$1.14

Intervallo di 1 settimana:

$0.75

$1.14

Portata 52W:

$0.6603

$2.43

Coherus Biosciences Inc Stock (CHRS) Company Profile

Nome

Coherus Biosciences Inc

Settore

Healthcare (1151)

Industria

Biotechnology (660)

Telefono

(650) 649-3530

Indirizzo

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Dipendente

228

Cinguettio

@coherus_bio

Prossima data di guadagno

2025-03-10

Ultimi documenti SEC

CHRS's Discussions on Twitter

Confronta CHRS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CHRS Coherus Biosciences Inc	1.12	112.95M	257.24M	-237.89M	-175.17M	-2.60
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-08-16	Downgrade	UBS	Buy → Neutral
2023-11-17	Iniziato	Robert W. Baird	Outperform
2023-11-08	Downgrade	Maxim Group	Buy → Hold
2023-07-24	Iniziato	Citigroup	Buy
2023-05-01	Iniziato	Truist	Buy
2023-03-28	Aggiornamento	UBS	Neutral → Buy
2022-06-14	Iniziato	UBS	Neutral
2022-03-07	Downgrade	JP Morgan	Overweight → Neutral
2020-07-16	Iniziato	BofA Securities	Neutral
2020-04-17	Iniziato	SunTrust	Buy
2019-08-13	Iniziato	Mizuho	Buy
2019-08-02	Reiterato	H.C. Wainwright	Buy
2019-08-02	Reiterato	Maxim Group	Buy
2019-06-11	Iniziato	Barclays	Overweight
2019-05-07	Iniziato	H.C. Wainwright	Buy
2018-08-28	Iniziato	H.C. Wainwright	Buy
2018-03-09	Reiterato	Maxim Group	Buy
2017-08-08	Reiterato	JP Morgan	Overweight
2017-06-13	Reiterato	Maxim Group	Buy
2017-05-05	Iniziato	BMO Capital Markets	Outperform
2016-10-19	Iniziato	Robert W. Baird	Outperform
2016-09-07	Iniziato	Maxim Group	Buy
2016-07-27	Iniziato	Citigroup	Buy
2016-01-20	Iniziato	Credit Suisse	Outperform

Mostra tutto

Coherus Biosciences Inc Borsa (CHRS) Ultime notizie

Apr 17, 2025

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha

Apr 17, 2025

Apr 16, 2025

Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment - insights.citeline.com

Apr 16, 2025

Apr 15, 2025

Coherus divests Udenyca franchise to Intas for up to $558.4m - MSN

Apr 15, 2025

Latham & Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance - Latham & Watkins LLP

Apr 15, 2025

Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals

Apr 15, 2025

Intas acquires Neulasta biosimilar Udenyca from Coherus BioSciences - World Pharmaceutical Frontiers

Apr 15, 2025

Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals

Apr 15, 2025

Apr 14, 2025

Coherus BioSciences (CHRS) Completes Divestiture of UDENYCA Fran - GuruFocus

Apr 14, 2025

Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million - marketscreener.com

Apr 14, 2025

Coherus completes strategic transformation - The Pharma Letter

Apr 14, 2025

Accord Biopharma Announces Completion Of Udenyca(Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus Biosciences, Inc., Expanding U.S. Biosimilar Portfolio - marketscreener.com

Apr 14, 2025

Intas Pharmaceuticals Acquires UDENYCA Business from Coherus BioSciences - Contract Pharma

Apr 14, 2025

Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio - PR Newswire

Apr 14, 2025

Coherus Biosciences Completes UDENYCA Franchise Divestiture - TipRanks

Apr 14, 2025

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise - GlobeNewswire

Apr 14, 2025

Coherus Lands Massive $558M Deal: Strategic Pivot to Oncology Extends Cash Runway to 2027 - Stock Titan

Apr 14, 2025

Apr 01, 2025

Coherus BioSciences to Repurchase $170 Million Convertible Notes - MarketScreener

Apr 01, 2025

Coherus BioSciences to repurchase $170 million in convertible notes - Investing.com India

Apr 01, 2025

Coherus BioSciences To Buy Back $170 Mln Of 1.500% Convertible Sr. Subordinated Notes - Nasdaq

Apr 01, 2025

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes - Bluefield Daily Telegraph

Apr 01, 2025

Coherus Unveils Massive $230M Debt Reduction Plan, Starting With $170M Note Buyback - Stock Titan

Apr 01, 2025

Mar 28, 2025

Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop - simplywall.st

Mar 28, 2025

Mar 27, 2025

Coherus BioSciences : Block Advisors by H&R Block to Provide Timely Support for The Home Depot’s Pro Xtra Loyalty Members - MarketScreener

Mar 27, 2025

Mar 25, 2025

Coherus to Present Data from a Phase 1 Dose Expansion Study - GlobeNewswire

Mar 25, 2025

Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial - Stock Titan

Mar 25, 2025

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue - BioWorld MedTech

Mar 25, 2025

Mar 24, 2025

Lobbying Update: $65,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Nasdaq

Mar 24, 2025

Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings - simplywall.st

Mar 24, 2025

Statutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True Position - Yahoo Finance

Mar 24, 2025

Mar 17, 2025

Coherus BioSciences, Inc. SEC 10-K Report - TradingView

Mar 17, 2025

Mar 14, 2025

Coherus BioSciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 14, 2025

Mar 13, 2025

Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale By Investing.com - Investing.com Australia

Mar 13, 2025

Coherus Prepares To Wave Goodbye To Udenyca – And 30% Of Its Staff - insights.citeline.com

Mar 13, 2025

Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale - Investing.com India

Mar 13, 2025

Mar 12, 2025